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Aquaporin 1 is a water channel protein. There was little aquaporin 1 immunoreactivity in normal brain parenchyma. In
astrocytomas, aquaporin 1 was expressed in microvessel endothelia and neoplastic astrocytes. In metastatic carcinomas,
aquaporin 1 was present in microvessel endothelia and reactive astrocytes. Aquaporin 1 may participate in the formation of
brain tumour oedema.
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Astrocytomas and metastatic carcinomas are the most common
brain tumours in adults and are associated with brain oedema,
which increases patient morbidity and mortality. The molecular
mechanisms responsible for this brain oedema are poorly under-
stood (Papadopoulos et al, 2001). A recently discovered family of
water channels proteins, called aquaporins (AQPs), may provide
a novel molecular explanation for the formation of human brain
tumour oedema.
The aquaporins (AQPs) are a family of 10 highly conserved
water channel proteins that provide the molecular pathway for
water permeability in water-transporting tissues (Verkman and
Mitra, 2001). Evidence of human diseases resulting from alterations
in AQP gene expression or regulation is limited. Mutations in
AQP2 cause nephrogenic diabetes insipidus and AQP0 mutations
have been associated with cataract formation (Verkman and Mitra,
2001). However, humans lacking the AQP1 protein appear pheno-
typically normal (Verkman and Mitra, 2001).
In rodents, only AQP4 and AQP1 are signiﬁcantly expressed in
normal brain. AQP4 is expressed in astrocyte endfeet around
microvessels and in the glial limiting membranes (Verkman and
Mitra, 2001). AQP1 is expressed in choroid plexus epithelium
and may be important in the formation of cerebrospinal ﬂuid
(Verkman and Mitra, 2001). In man, there is massive upregulation
of AQP4 expression in tumour cells in high-grade astrocytomas
and reactive astrocytes around metastatic carcinomas (Saadoun et
al, 2002). However, little is known about AQP1 expression in
normal human brain and human brain tumours.
MATERIALS AND METHODS
Immunohistochemistry was used to investigate the expression of
AQP1 in morphologically normal human brain (n=5), low-
(n=5) and high-grade (n=5) astrocytomas and metastatic carcin-
omas (n=5). The study was approved by St. George’s Healthcare
Ethics Committee. Astrocytomas were classiﬁed as low (grades
I–II) or high (grades III–IV) grade according to the Daumas-
Duport criteria. Non-neoplastic cerebral cortex was obtained from
patients who underwent temporal lobectomies for intractable
epilepsy (n=3) and from the entry sites of ventricular drains
(n=2). All patients with brain tumours (n=15) received dexametha-
sone, compared with three out of ﬁve of those who contributed
histologically normal brain tissue. Tissue specimens were ﬁxed in
buffered formalin/saline and processed into parafﬁn wax. Tissue
sections (10 mm) were cut and incubated with a polyclonal rabbit
anti-AQP1 antibody (AB3065, Chemicon), followed by a goat
anti-rabbit biotinylated antibody (Sigma), avidin–biotin–horse-
radish peroxidase and diaminobenzidine tetrachloride/H2O2.
Sections from each subject were also immunoreacted with a poly-
clonal rabbit anti-glial ﬁbrillary acidic protein (GFAP) primary
antibody (Dako) to aid identiﬁcation of the cells expressing
AQP1. Omitting the primary or secondary antibody abolished
staining. Assessment of the sections was performed ‘blind’ by
two investigators. Kendall’s tau-B test was used to quantify the
relationship between tied non-parametric qualitative data.
RESULTS
In all specimens AQP1 was detected in erythrocyte membranes. In
sections of normal brain, AQP1 immunolabelling appeared as
brown deposit over the endothelium of a few (533%) micro-
vessels (Figure 1B). There was no immunolabelling of the brain
paren-chyma (Figure 1A,B). In low-grade astrocytomas, AQP1
immunoreactivity was present in tumour cells, mostly in the region
of the cell membrane (Figure 1C). In high-grade astrocytomas,
AQP1 immunoreactivity was massively upregulated and distributed
throughout the cytoplasm of neoplastic cells (Figure 1D). The
amount of AQP1 in astrocytomas strongly correlated with the
grade of malignancy (Table 1). In all metastatic carcinomas,
AQP1 was expressed in microvessel endothelium (Figure 1E) and
reactive astrocytes (Figure 1F–H). AQP1 was not detected in
cancer cells.
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Figure 1 Immunostaining (brown) for (A–G) AQP1 and (H) GFAP with cresyl violet counterstain. (A) and (B) Microvessels from normal brain tissue. In
(A), which is typical of most microvessels in normal brain, only the red blood cell membranes stain for AQP1. In a few microvessels in normal brain, such as
(B), the endothelial cell membranes also stain for AQP1. AQP1 immunoreactivity is upregulated in (C) low-grade and (D) high-grade astrocytoma. (E–H)
Photomicrographs of carcinoma metastases to brain. In (E) the microvessel endothelium and red blood cells immunostain for AQP1. (F) Shows an AQP1
immunopositive astrocyte trapped between cancer cells. In (G) reactive astrocytes immunostain for AQP1. (H) Shows that the cells which express AQP1
also stain for GFAP. Bars=10 mm( A,B), 90 mm( C–E), 30 mm( F–H). AC=astrocytoma cells, CC=carcinoma cells, EC=endothelial cells, RA=reactive
astrocytes, RC=red blood cells.
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The current results agree with data from a study of AQP1 expres-
sion in glioblastoma and breast cancer transplanted into mouse
brain (Endo et al, 1999). In that study, AQP1 immunoreactivity
was found in glioblastoma cells and microvascular endothelial cells,
but not normal brain parenchyma or normal microvessel endothe-
lium. AQP1 mRNA levels have recently been shown to be increased
in human glioblastoma, compared with normal human brain
(Markert et al, 2001).
There was little or no AQP1 expression in normal brain micro-
vessel endothelium, which is consistent with its low permeability to
many substances. The microvascular endothelium of brain tumours
has an impaired blood–brain barrier function (Papadopoulos et al,
2001) and the current results suggest that its permeability to water
may also be increased. The signals that induce AQP1 expression in
the endothelium of brain tumours are unknown, but might include
vascular endothelial growth factor, which is produced by tumour
cells and is known to increase vascular permeability.
The presence of AQP1 immunoreactivity in both cell membrane
and cytoplasm of high-grade astrocytoma cells suggests a high
turnover of AQP1 protein. Assuming that AQP1 protein is func-
tional in brain tumours, AQP1 may be contributing to the ﬂow
of oedema ﬂuid through the tissue. AQP1 water channel blockers
might thus be potent anti-brain tumour oedema agents.
Glucocorticoids are commonly used to reduce brain tumour
oedema, but their mechanism of action is unclear. Since all of
the tumour patients received dexamethasone, it was not possible
to determine the effect of glucocorticoids on AQP1 expression.
Interestingly, the AQP1 promoter, sequenced from human erythro-
leukaemia cells, possesses steroid responsive elements (Moon et al,
1997). It is, therefore, possible that the anti-brain tumour oedema
action of glucocorticoids is at least partly explained by alterations
in AQP1 expression.
Further studies are needed to clarify the mechanisms responsible
for the upregulation of AQP1 (present study) and AQP4 (Saadoun
et al, 2002) expression in brain tumours and the contribution of
these water channels to brain tumour oedema. Co-cultures of
neurons, astrocytes, endothelial or cancer cells may elucidate the
role of cell-cell interactions in the control of water channel expres-
sion. Brain tumour models comparing wild-type mice with AQP1
and AQP4 knockout mice may shed light on the contribution of
these water channels to brain tumour oedema. High throughput
screening of combinatorial libraries and other techniques are
underway to identify water channel blockers, which might reduce
brain tumour oedema.
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Table 1 AQP1 expression increases with the progression from normal brain to low-grade to high-grade as-
trocytoma. The proportion of microvessels expressing AQP1 was graded 0 (433%), +(34–66%) or
++(567%). Astrocytes/astrocytoma cells were graded 0 (nil), +(mostly cell membrane), ++(mostly cell mem-
brane and cytoplasm) for the pattern of AQP1 immunostaining and 450%, 450% for the proportion of cells
expressing AQP1
Microvessels Astrocyte Astrocytoma
0 + ++ 0 + ++ 450% 450%
Normal 5 0 0 5 0 0 5 0
Low-grade astrocytoma 1 4 0 1 4 0 2 3
High-grade astrocytoma 1 1 3 0 2 3 0 5
Kendall tau-B (P) 0.713 (0.002) 0.844 (50.001) 0.772 (0.002)
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